MaxCyte (NASDAQ:MXCT) Issues Quarterly Earnings Results

MaxCyte (NASDAQ:MXCT) announced its quarterly earnings data on Tuesday. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.06, FiscalAI reports. MaxCyte had a negative net margin of 135.14% and a negative return on equity of 22.15%. The business had revenue of $6.22 million during the quarter, compared to the consensus estimate of $7.28 million.

Here are the key takeaways from MaxCyte’s conference call:

• MaxCyte reported Q1 revenue of $9.7 million, which met management’s expectations, and reiterated full-year 2026 guidance of $30 million-$32 million in total revenue.
• Core revenue fell 25% year over year to $6.2 million, pressured by inventory management at its largest SPL customer and the impact of discontinued SPL programs.
• The company highlighted improving momentum in its SPL pipeline, with 29 partners and expectations for at least three new SPL signings in 2026, plus multiple later-stage programs advancing toward registrational trials.
• New products are starting to contribute: ExPERT DTx is seeing encouraging early adoption, while SeQure posted $0.6 million in Q1 revenue and management said the recent FDA draft guidance should be a structural positive for the business.
• MaxCyte is benefiting from a much leaner cost structure, with Q1 operating expenses down to $14.3 million from $21.2 million a year ago, $147.7 million in cash and investments, and a newly authorized $10 million share repurchase program.

MaxCyte Stock Up 25.9%

Shares of NASDAQ MXCT traded up $0.21 during midday trading on Wednesday, reaching $1.04. 5,829,966 shares of the company were exchanged, compared to its average volume of 1,033,298. The stock’s 50-day moving average price is $0.80 and its 200-day moving average price is $1.14. The stock has a market cap of $110.87 million, a P/E ratio of -2.40 and a beta of 1.37. MaxCyte has a one year low of $0.64 and a one year high of $2.40.

Institutional Trading of MaxCyte

A number of hedge funds and other institutional investors have recently modified their holdings of MXCT. Kennedy Capital Management LLC bought a new stake in shares of MaxCyte during the third quarter worth $3,330,000. AXA S.A. grew its stake in shares of MaxCyte by 123.2% in the second quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after purchasing an additional 1,215,481 shares during the last quarter. Millennium Management LLC grew its stake in shares of MaxCyte by 1,082.6% in the fourth quarter. Millennium Management LLC now owns 1,292,773 shares of the company’s stock worth $2,004,000 after purchasing an additional 1,183,461 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of MaxCyte in the fourth quarter worth $1,594,000. Finally, UBS Group AG grew its stake in shares of MaxCyte by 186.3% in the third quarter. UBS Group AG now owns 474,487 shares of the company’s stock worth $750,000 after purchasing an additional 308,769 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wall Street Zen downgraded shares of MaxCyte from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Craig Hallum decreased their target price on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, March 25th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research note on Friday, April 24th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $5.50.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.